Answers are grounded in this paper and cite their sources.
There is a paucity of data regarding the pharmaceutical care needs of people with SL. Unmet pharmaceutical care needs put people with SL at increased risk of harm from their medicines. A detailed understanding of the needs of people with SL is required which will inform future delivery of pharmaceutical care for this vulnerable population.
No takes yet. Share an insight, caveat, or question.
Killick et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: